Paoletti E, Tartaglia J, Taylor J
Virogenetics Corporation, Rensselaer Technology Park, Troy, NY.
Dev Biol Stand. 1994;82:65-9.
This paper describes the development and in vitro/in vivo characterization of two highly attenuated recombinant poxvirus vectors. The vectors, NYVAC and ALVAC, exhibit a restricted host range and a greatly enhanced degree of attenuation following inoculation into a range of animal species by a variety of routes. The safety profile of these vectors, together with their demonstrated ability to induce both humoral and cell-mediated immune responses to extrinsic antigens, makes them ideal candidates for use as vaccines in both human and veterinary disease situations.
本文描述了两种高度减毒的重组痘病毒载体的研发及其体外/体内特性。NYVAC和ALVAC这两种载体表现出受限的宿主范围，并且通过多种途径接种到一系列动物物种后，其减毒程度大大增强。这些载体的安全性，以及它们诱导针对外源抗原的体液免疫和细胞介导免疫反应的能力，使其成为人类和兽医学疾病疫苗的理想候选者。
